Clinical Study
Testing a Study Drug Vixarelimab for People with Idiopathic Pulmonary Fibrosis and People with Systemic Sclerosis-Associated Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease are two types of lung diseases that worsen over time. This study will test a study drug called Vixarelimab to treat people with these diseases. The study wants to see if the drug will help people with the diseases and is safe. People in the study will be placed into two groups those with Idiopathic Pulmonary Fibrosis or Systemic Sclerosis-Associated Interstitial Lung Disease. People within each group will be randomly chosen to be treated with Vixarelimab or a placebo. The placebo looks like the study drug but does not have the medication. Being in the study requires in-person study visits at the study clinic for about 59 weeks. Medical tests will be done to track the health of participants.
For more information contact:
Chloe Kirkpatrick
chloe.kirkpatrick@hsc.utah.edu
8015815811
IRB#: IRB_00172671
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2024-04-17 06:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Childbearing age must use specific birth control
- Ages 40 to 85 years old with Idiopathic Pulmonary Fibrosis
- Ages 18 to 85 years old with Systemic Sclerosis-Associated Interstitial Lung Disease
- Able to attend in person at study clinic
Exclusion Criteria:
- Pregnant or breastfeeding or wanting to become pregnant during the study or within 60 days after the final dose of Vixarelimab
- Use of a specific dosage of corticosteroids like prednisone (medications used to reduce swelling) within 2 weeks before starting the study
- Major surgery within 8 weeks before participation or planned major surgery during the study
- History of lung transplant
Will I be paid for my time?
Yes